Mesalamine – USA

Mesalamine – USA

On Oct. 24, 2017, Judge Rodney Gilstrap of Eastern district of Texas dismissed Allergan’s suit against Teva & Mylan for alleged infringement of Delzicol®(Mesalamine delayed release capsules, 400 mg) patent. Delzicol is used in the treatment of ulcerative colitis. The patent-in -suit was US 6,649,180 listed in Orange Book which is expiring on Apr 13, 2020. US’180 patent claims a hard capsule formed of a film composition comprising a hydroxypropyl methyl cellulose as a base, a gelling agent, and a gelling aid with certain percentage of methoxyl groups and hydroxypropoxyl groups.

Previously on Sep 28, 2017, the magistrate judge (Roy Payne) granted the motions for summary judgment of non-infringement with respect to US’180 patent in favor of Teva & Mylan.After that bench trial was concluded on Oct 24, 2017 & Judge Gilstrap affirmed the decision of magistrate judge.

Other generic player is Zydus which has settled the case in Dec 2016.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved